0.27
+3.92%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Trajan Group Holdings
Its shares trade on ASX under the ticker TRJ.AX. It has been listed since 7 June 2021. In the fiscal year to 30 June 2026, it reported revenue of A$161.4m and a net loss of A$623,000. At that date it held total assets of A$183.9m and shareholders' equity of A$98.5m.
Trajan Group Holdings Ltd. engages in the designing, manufacturing and supply of products and solutions that enhance scientific measurement. The portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The firm operates through two segments: Analytical Products and Life Science Solutions. The Analytical Products segment is involved in the designing, manufacturing, distribution and selling of analytical components and consumables. Life Science Solutions segment is involved in the designing, manufacturing, distribution and selling of pathology, automation workflow solutions, micro sampling devices, testing and data analysis. The company develops medical devices for microsample collection, pathology products, precision components for mass spectrometry, and automated workflow solutions. The firm offers various services, including technical, commercial, facilities, and collaboration.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 7 Jun 2021
- Employees
- 653
Leadership
Pay as last reported
- Mr. John EalesIndependent Non-Executive Chairman of the BoardA$130,954
- Mr. Stephen TomisichGroup Chief Executive Officer, Managing Director, Executive Director, since 2021A$640,542
- Mr. Alister HodgesChief Financial Officer, Joint Company SecretaryA$339,350
- Mr. Nigel GilliganChief Operations OfficerA$413,465
- Mr. Sam EvansSenior Vice President - Business Development$427,731
- Dr. Andrew GooleyChief Scientific Officer, since 2021A$355,536
- Mr. Robert LyonHead - Corporate Development, General Counsel, Executive Director, since 2014A$349,950
- Mr. Mark LicciardoJoint Company Secretary
- Dr. Rohit KhannaIndependent Non-Executive DirectorA$80,636
- Ms. Tiffiny LewinIndependent Non-Executive DirectorA$80,636
- Ms. Sara WattsIndependent Non-Executive DirectorA$100,636
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates in the Health Care sector with a focus on Life Sciences Tools & Services.
- Offers a diverse portfolio including analytical components, consumables, and medical devices.
- Has two operational segments: Analytical Products and Life Science Solutions.
Weaknesses
- City information is unknown for the company headquarters.
- IPO occurred in 2021, indicating a relatively new public company.
- No specific employee count is provided beyond 653, which may not reflect current staffing.
Opportunities
- Growth potential in scientific measurement solutions for biological, food, and environmental analysis.
- Expansion of services such as technical, commercial, facilities, and collaboration offerings.
- Increasing demand for pathology and automation workflow solutions in the life sciences industry.
Threats
- Reliance on untrusted source descriptions for company operations.
- Potential challenges in a competitive market for life sciences tools and services.
- New public company status may face volatility in stock performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.